Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardinal HealthLTS:0HTG +1.84%81 EV-to-EBIT is 24.94 as of Jul. 26, 2026, which is 46% above its 10-year median of 17.14. GuruFocus rates LTS:0HTG with a GF Score™ of 81/100 and a GF Value™ of $141.39 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 94 Medical Distribution companies, Cardinal Health ranks worse than 87.23% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cardinal Health's Enterprise Value for the quarter that ended in Mar. 2026 was $54,497 Mil.
Cardinal Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,347 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardinal Health EV-to-EBIT Related Terms
Cardinal Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cardinal Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cardinal Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardinal Health EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cardinal Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cardinal Health's EV-to-EBIT falls into.
Cardinal Health's current Enterprise Value is $58,545 Mil.
Cardinal Health's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,347 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardinal Health (LTS:0HTG) has a EV-to-EBIT of 24.94 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardinal Health and its competitors. This is 46% above median its historical median of 17.14. According to the industry distribution chart, Cardinal Health ranks #82 out of 94 companies in the Medical Distribution industry, placing it in the top 87.2%.
Is Cardinal Health's EV-to-EBIT too high?
Cardinal Health's current EV-to-EBIT of 24.94 is 46% above median its 10-year median of 17.14. The Medical Distribution industry median EV-to-EBIT is 11.53. Cardinal Health's value of 24.94 is 116.3% above this industry median. Based on the distribution chart, Cardinal Health ranks #82 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cardinal Health has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardinal Health's EV-to-EBIT compare to COR and MCK?
According to the Medical Distribution industry distribution chart, Cardinal Health ranks #82 out of 94 companies for EV-to-EBIT. This places Cardinal Health in the lower half of its industry. The industry median EV-to-EBIT is 11.53. Cardinal Health's value of 24.94 is 116.3% above this benchmark. While the company's 10-year median is 17.14 vs. the industry median of 11.53, Cardinal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.53, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardinal Health's current EV-to-EBIT of 24.94 is 116.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardinal Health and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardinal Health's current EV-to-EBIT is 24.94, which is 46% above median its own 10-year median of 17.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardinal Health stock overvalued right now?
Based on GuruFocus' analysis, Cardinal Health (LTS:0HTG) is currently considered Significantly Overvalued. The stock's GF Value™ is $141.39, compared to a current price of $227.41 — trading 60.8% above its estimated fair value. The current EV-to-EBIT is 24.94, which is 46% above median its 10-year median of 17.14 and 116.3% above the Medical Distribution industry median of 11.53. Cardinal Health's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cardinal Health (LTS:0HTG), the current EV-to-EBIT is 24.94 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardinal Health (LTS:0HTG) Overvalued in 2026?
Based on GuruFocus' analysis, Cardinal Health stock appears to be overvalued.
The current stock price of $227.41 is trading 60.8% above its estimated GF Value™ of $141.39.
GuruFocus considers Cardinal Health to be Significantly Overvalued.
Key valuation signals for LTS:0HTG:
EV-to-EBIT: 24.94 (46% above median its 10-year median of 17.14)
GF Value™: $141.39 vs. price of $227.41 (60.8% above fair value)
Industry Position: 116.3% above the Medical Distribution median (#82 of 94)
No single metric tells the full story. See the LTS:0HTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
81GF Score
Get the complete analysis for LTS:0HTG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTG has been successfully added to your 
